Clinical Trial: Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate
Study Status: Completed
Recruit Status: RECRUITING
Condition: Prostate Adenocarcinoma
Study Type: INTERVENTIONAL
Official Title: Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate (PORT-MAP)
Brief Summary:
To evaluate the effect of Osanetant on testosterone levels in men with prostate cancer within 28 days of therapy.
Read more